Skip to content

Celldex Therapeutics, Inc.

CLDX

CIK 0000744218

← back to feed
Revenue (TTM)
$4.63M
−78.0% YoY Q1 Apr 2026
Net Income (TTM)
−$256.13M
−63.9% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$3.85
−59.2% YoY Q1 Apr 2026
Gross Margin
95.7%
Q1 Apr 2026
Operating Margin
-6,146.6%
Q1 Apr 2026
Net Margin
-5,530.7%
Q1 Apr 2026
Free Cash Flow (TTM)
−$192M
Q1 Apr 2026
Cash
$35.73M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
78.49M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings